WO2002096469A3 - Gene delivery via a baculovirus vector - Google Patents

Gene delivery via a baculovirus vector Download PDF

Info

Publication number
WO2002096469A3
WO2002096469A3 PCT/GB2002/002504 GB0202504W WO02096469A3 WO 2002096469 A3 WO2002096469 A3 WO 2002096469A3 GB 0202504 W GB0202504 W GB 0202504W WO 02096469 A3 WO02096469 A3 WO 02096469A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene delivery
delivery via
baculovirus vector
baculovirus
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2002/002504
Other languages
French (fr)
Other versions
WO2002096469A2 (en
Inventor
Seppo Yla-Herttuala
Kari Juhani Airenne
Pauliina Lehtolainen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ark Therapeutics Ltd
Original Assignee
Ark Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2001/002383 external-priority patent/WO2001090390A1/en
Priority claimed from GBGB0128620.2A external-priority patent/GB0128620D0/en
Application filed by Ark Therapeutics Ltd filed Critical Ark Therapeutics Ltd
Priority to CA002448985A priority Critical patent/CA2448985A1/en
Priority to EP02730459A priority patent/EP1392837A2/en
Priority to AU2002302780A priority patent/AU2002302780A1/en
Priority to US10/478,978 priority patent/US20040208905A1/en
Publication of WO2002096469A2 publication Critical patent/WO2002096469A2/en
Publication of WO2002096469A3 publication Critical patent/WO2002096469A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A baculovirus is used for gene therapy of a condition that can be mediated via the spinal cord or CNS.
PCT/GB2002/002504 2001-05-29 2002-05-28 Gene delivery via a baculovirus vector Ceased WO2002096469A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002448985A CA2448985A1 (en) 2001-05-29 2002-05-28 Gene delivery via a baculovirus vector
EP02730459A EP1392837A2 (en) 2001-05-29 2002-05-28 Gene delivery via a baculovirus vector
AU2002302780A AU2002302780A1 (en) 2001-05-29 2002-05-28 Gene delivery via a baculovirus vector
US10/478,978 US20040208905A1 (en) 2001-05-29 2002-05-28 Gene delivery of a viral vector

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/GB2001/002383 WO2001090390A1 (en) 2000-05-26 2001-05-29 Use of baculovirus vectors in gene therapy
GBPCT/GB01/02383 2001-05-29
GB0128620.2 2001-11-29
GBGB0128620.2A GB0128620D0 (en) 2001-11-29 2001-11-29 Gene delivery of a viral vector

Publications (2)

Publication Number Publication Date
WO2002096469A2 WO2002096469A2 (en) 2002-12-05
WO2002096469A3 true WO2002096469A3 (en) 2003-03-06

Family

ID=26245653

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/002504 Ceased WO2002096469A2 (en) 2001-05-29 2002-05-28 Gene delivery via a baculovirus vector

Country Status (2)

Country Link
EP (1) EP1392837A2 (en)
WO (1) WO2002096469A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1648948B1 (en) 2003-07-18 2012-02-08 Agency for Science, Technology and Research Thermosensitive polymers for therapeutic use and methods of preparation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998020027A2 (en) * 1996-11-01 1998-05-14 Eurogene Limited Therapeutic use of an agent that stimulates no or prostacyclin production and delivery device
DE19735593A1 (en) * 1997-08-15 1999-02-18 Hepavec Ag Fuer Gentherapie New Baculovirus vector for gene therapy
WO2000005394A1 (en) * 1998-07-24 2000-02-03 Aventis Pharma S.A. Vectors derived from baculovirus and use for transferring nucleic acids into nerve cells of vertebrates
WO2001090390A1 (en) * 2000-05-26 2001-11-29 Ark Therapeutics Limited Use of baculovirus vectors in gene therapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998020027A2 (en) * 1996-11-01 1998-05-14 Eurogene Limited Therapeutic use of an agent that stimulates no or prostacyclin production and delivery device
DE19735593A1 (en) * 1997-08-15 1999-02-18 Hepavec Ag Fuer Gentherapie New Baculovirus vector for gene therapy
WO2000005394A1 (en) * 1998-07-24 2000-02-03 Aventis Pharma S.A. Vectors derived from baculovirus and use for transferring nucleic acids into nerve cells of vertebrates
WO2001090390A1 (en) * 2000-05-26 2001-11-29 Ark Therapeutics Limited Use of baculovirus vectors in gene therapy

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
AIRENNE K J ET AL: "Baculovirus-mediated periadventitial gene transfer to rabbit carotid artery", BIOSIS, XP001096262 *
BOYCE F M ET AL: "BACULOVIRUS-MEDIATED GENE TRANSFER INTO MAMMALIAN CELLS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 93, March 1996 (1996-03-01), pages 2348 - 2352, XP000783676, ISSN: 0027-8424 *
HOFMANN C ET AL: "Baculovirus-mediated gene transfer in the presence of human serum or blood facilitated by inhibition of the complement system", BIOSIS, XP002175451 *
KOST T A ET AL: "Recombinant baculoviruses as expression vectors for insect and mammalian cells.", CURRENT OPINION IN BIOTECHNOLOGY. ENGLAND OCT 1999, vol. 10, no. 5, October 1999 (1999-10-01), pages 428 - 433, XP002222109, ISSN: 0958-1669 *
LO WARREN D ET AL: "Adeno-associated virus-mediated gene transfer to the brain: Duration and modulation of expression", BIOSIS, XP002175452 *
MCMAHON J M ET AL: "Inflammatory responses following direct injection of plasmid DNA into skeletal muscle", BIOSIS, XP002175450 *
ONOUE ET AL.: "Expression and function of recombinant endothelial nitric oxid synthase gene in canine basilar artery after experimental subarachnoid hemorrhage", STROKE, vol. 29, no. 9, September 1998 (1998-09-01), pages 1959 - 1966, XP002222108 *
OOBOSHI H ET AL: "Adenovirus-mediated gene transfer to cerebral circulation.", MECHANISMS OF AGEING AND DEVELOPMENT. IRELAND 31 JUL 2000, vol. 116, no. 2-3, 31 July 2000 (2000-07-31), pages 95 - 101, XP002222107, ISSN: 0047-6374 *
PIERONI LUISA ET AL: "In vivo gene transfer in mouse skeletal muscle mediated by baculovirus vectors", BIOSIS, XP002175453 *
SANDIG V ET AL: "GENE TRANSFER INTO HEPATOCYTES AND HUMAN TISSUE BY BACULOVIRUS VECTORS", HUMAN GENE THERAPY, XX, XX, vol. 7, no. 16, 20 October 1996 (1996-10-20), pages 1937 - 1945, XP000674903, ISSN: 1043-0342 *
SHOJI I ET AL: "Efficient transfer ino various mammalian cells, including non-hepatic cells, by baculovirus vectors", JOURNAL OF GENERAL VIROLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, READING, GB, vol. 78, no. 10, October 1997 (1997-10-01), pages 2657 - 2664, XP002100056, ISSN: 0022-1317 *

Also Published As

Publication number Publication date
WO2002096469A2 (en) 2002-12-05
EP1392837A2 (en) 2004-03-03

Similar Documents

Publication Publication Date Title
AU2001292881A1 (en) Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
AU2002307212A1 (en) Stackable transmission line hanger field of the invention
AU2002234643A1 (en) Amphoteric liposomes and the use thereof
AU2002303502A1 (en) Improved leads for the treatment of patients with chf
AU2002255918A1 (en) Human serine/threonine kinase
AU2002256638A1 (en) Pyridinyl pyrazoles useful for the treatment of copd
AU2003273983A1 (en) Viral vectors and the use of the same for gene therapy
WO2002060483A3 (en) Perylenequinones for use as photosensitizers and sonosensitizers
AU2002240942A1 (en) Improved delivery of benefit agents
WO2002096469A3 (en) Gene delivery via a baculovirus vector
AU2003269257A1 (en) Use of cap-1 for the therapy of asthma
AU2002353315A1 (en) Disruption of the phosphodiesterase 10 gene
AU2002316788A1 (en) Retroviral vectors for gene therapy
AU2002233499A1 (en) Single nucelotide polymorphisms of the seek1 gene associated withpsoriasis
AU2002361969A1 (en) Stabilization of dispersions of halogen-containing polymers
AU2002363081A1 (en) Antimicrobial peptides from the venom of the spider cupiennius salei
AU2002304733A1 (en) Amino-aza-cyclohexanes for the treatment of malaria
AU2002303821A1 (en) Aryl-8-azabicyclo(3.2.1)octanes for the treatment of depression
AU2002331162A1 (en) Human serine/threonine kinase
AU2002304447A1 (en) Treatment of liquids
AU2002331285A1 (en) Use of 1,1,1,3,3-pentafluorobutan
AU2002316724A1 (en) Ophthalmic use of 5 fluorourcil
AU2002316239A1 (en) Improved ergonomic chair background of the invention
AU2002311024A1 (en) Silicon dioxide dispersion
AU2002303095A1 (en) Improved prostanoid therapies for the treatment of glaucoma

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002730459

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2448985

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2002730459

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10478978

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2002730459

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP